These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32160956)

  • 21. The use of colchicine as an anti-inflammatory agent for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis.
    Goh CXY; Tan YK; Tan CH; Leow AST; Ho JSY; Tan NHW; Goh S; Ho AFW; Sharma VK; Chan BPL; Yeo LLL; Tan BYQ
    J Thromb Thrombolysis; 2022 Jul; 54(1):183-190. PubMed ID: 35538274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Colchicine on Cardiovascular Outcomes in Patients with Coronary Artery Disease: A Systematic Review and One-Stage and Two-Stage Meta-Analysis of Randomized-Controlled Trials.
    Teo YN; Teo YH; Syn NL; Goh MW; Yoong CSY; Lee CH; Chan MY; Chai P; Yeo TC; Sia CH
    High Blood Press Cardiovasc Prev; 2021 Jul; 28(4):343-354. PubMed ID: 34003455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meta-analysis Evaluating the Utility of Colchicine in Secondary Prevention of Coronary Artery Disease.
    Xia M; Yang X; Qian C
    Am J Cardiol; 2021 Feb; 140():33-38. PubMed ID: 33137319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Colchicine treatment after myocardial infarction : Colchicine Cardiovascular Outcomes Trial (COLCOT)].
    Klingenberg R; Nitschmann S
    Internist (Berl); 2020 Jul; 61(7):766-769. PubMed ID: 32103281
    [No Abstract]   [Full Text] [Related]  

  • 25. Evaluating the Utility of Colchicine in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
    Bao YL; Gu LF; Du C; Wang YX; Wang LS
    J Cardiovasc Pharmacol; 2022 Nov; 80(5):639-647. PubMed ID: 35881909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Colchicine therapy in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.
    Al-Abdouh A; Barbarawi M; Khan SU; Osman M; Upadhrasta S; Solipuram V; Abusnina W; Radaideh Q; Zhao D; Michos ED
    Coron Artery Dis; 2021 Aug; 32(5):441-447. PubMed ID: 32732517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colchicine for Secondary Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Samuel M; Tardif JC; Bouabdallaoui N; Khairy P; Dubé MP; Blondeau L; Guertin MC
    Can J Cardiol; 2021 May; 37(5):776-785. PubMed ID: 33075455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Colchicine in Reducing Inflammatory Biomarkers and Cardiovascular Risk in Coronary Artery Disease: A Meta-analysis of Clinical Trials.
    Sethuramalingam S; Maiti R; Hota D; Srinivasan A
    Am J Ther; 2023 May; 30(3):e197-e208. PubMed ID: 34264887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
    Berger JS; Roncaglioni MC; Avanzini F; Pangrazzi I; Tognoni G; Brown DL
    JAMA; 2006 Jan; 295(3):306-13. PubMed ID: 16418466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Effectiveness of Anti-Inflammatory Drug Treatments in Coronary Heart Disease Patients: A Systematic Review and Network Meta-Analysis.
    Wudexi I; Shokri E; Abo-Aly M; Shindo K; Abdel-Latif A
    Mediators Inflamm; 2021; 2021():5160728. PubMed ID: 33510581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of vitamin E in the prevention of coronary events and stroke. Meta-analysis of randomized controlled trials.
    Alkhenizan AH; Al-Omran MA
    Saudi Med J; 2004 Dec; 25(12):1808-14. PubMed ID: 15711645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Different Dosing Regimens of Colchicine in Patients With Coronary Artery Disease: A Network Meta-analysis of 15 Randomized Controlled Trials.
    Wang S; Mu Y; Tan L; Hao J
    J Cardiovasc Pharmacol; 2023 Jul; 82(1):13-22. PubMed ID: 37026756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Colchicine in Prevention of Secondary Cardiovascular Outcomes Among Patients With Coronary Vessel Disease: A Meta-Analysis.
    Sattar L; Memon RA; Ashfaq F; Hamdani SSQ; Rahim Vohra R; Ashraf J; Khan B; Khurshid Ahmed N; Khan A
    Cureus; 2022 Jul; 14(7):e26680. PubMed ID: 35949770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.
    Nidorf SM; Thompson PL
    Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of colchicine in the treatment of acute myocardial infarction: A protocol for systematic review and meta-analysis.
    Xiong H; Huang X; Rao L; Zhao J
    Medicine (Baltimore); 2021 Apr; 100(14):e25429. PubMed ID: 33832144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials.
    Mahmoud AN; Elgendy AY; Rambarat C; Mahtta D; Elgendy IY; Bavry AA
    PLoS One; 2017; 12(4):e0175283. PubMed ID: 28403216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials.
    Barbarawi M; Kheiri B; Zayed Y; Gakhal I; Al-Abdouh A; Barbarawi O; Rashdan L; Rizk F; Bachuwa G; Alkotob ML
    High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):283-291. PubMed ID: 31280451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R; Baldi C; Di Biase G; Ariano C; Cioppa C; Giasi A; Valente L; Cantatrione S
    Minerva Cardioangiol; 2014 Dec; 62(6):437-48. PubMed ID: 25029569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin.
    McGrath E; O'Conghaile A; Eikelboom JW; Dinneen SF; Oczkowski C; O'Donnell MJ
    Cerebrovasc Dis; 2011; 32(1):22-7. PubMed ID: 21576939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.